MapLight Reports FY25 Results, Expects Multiple Phase 2 Readouts In 2026

MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, compared to $21.2 million in the prior year period. The company expects multiple Phase 2 readouts in 2026, including topline results for its schizophrenia and Alzheimer's disease psychosis trials, and completion of enrollment for its autism spectrum disorder trial. MapLight ended 2025 with $453.1 million in cash and expects this to fund operations through 2027. The stock closed at $18.14 on Wednesday, down 7.50% in pre-market trading.